Evidence map›Paper›PMID 33458714›Full record

ArticlePublic health in practice (Oxford, England)2020

Health related quality of life in individuals at high risk of chronic liver disease: Impact of a community diagnostic pathway.

Tildesley Zoe, Chalmers Jane, Harris Rebecca, West Joe, Indra Neil Guha, Joanne Rebecca Morling

Abstract read
In one paragraph

Article in Public health in practice (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Patients with MASH experience worse health-related quality of life: a multinational real-world study using LiverMultiScan.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tildesley ZoeDivision of Epidemiology and Public Health, School of Medicine, University of Nottingham, City Hospital, Clinical Sciences Building 2, Nottingham, NG5 1PB, UK.
Chalmers JaneNIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, NG7 2UH, UK.
Harris RebeccaNIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, NG7 2UH, UK.
West JoeDivision of Epidemiology and Public Health, School of Medicine, University of Nottingham, City Hospital, Clinical Sciences Building 2, Nottingham, NG5 1PB, UK.
Indra Neil GuhaNIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, NG7 2UH, UK.
Joanne Rebecca MorlingDivision of Epidemiology and Public Health, School of Medicine, University of Nottingham, City Hospital, Clinical Sciences Building 2, Nottingham, NG5 1PB, UK.

Funding

Medical Research Council MR/P008348/1
6 · The paper itself

Abstract

objectivesThere is a lack of understanding of health related quality of life (HRQoL) in chronic liver disease (CLD). With the rising prevalence of alcohol and obesity driven CLD, and the increasing ability to screen for fibrosis, it is important to understand the impact of the diagnostic process for patients. STUDY

designProspective cohort study.

methodsA cohort study conducted utilising the Nottingham Adult Liver Disease Stratification Pathway, UK. All patients referred as high risk for CLD (due to metabolic, alcohol or abnormal liver enzymes) completed the EQ-5D before diagnosis and at three and 12 months after. HRQoL was investigated by domain, CLD severity (transient elastography) and temporally.

results493 patients participated with 300 (60.9%) completing at least one follow-up HRQoL assessment.Pre-diagnosis the median (IQR) utility index was 0.75 (0.61-0.85) and visual analogue scale was 75/100 (60-90). The median utility index was significantly lower amongst those with advanced liver disease compared to those without at all time points (baseline 0.68 vs 0.77, three-months 0.65 vs 0.79, 12-months 0.69 vs 0.84, all p ​< ​0.05). The majority of decrements in HRQoL score were in the pain domain.

conclusionsThere was no reduction, over three or 12 months, in HRQoL identified amongst high-risk individuals progressing through the diagnostic pathway. Overall the HRQoL of participants at high risk for the development of significant CLD was lower than the UK and regional (East Midlands) norms. Furthermore, we found reduced HRQoL in those going on to receive a diagnosis of advanced liver disease compared to those without.

Indexed as

Chronic liver diseaseDiagnostic testsPreventionQuality of lifeScreening

Identifiers

PMID33458714
PMCPMC7790448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.